Katalysen Ventures

Aktieägare som vill delta i Katalysen Ventures bolagsstämma måste vara registrerade i aktieboken hos Euroclear Sweden AB senast den 5 november 2025. Anmälan om deltagande bör ske senast den 7 november 2025 via post eller e-post. För aktieägare med förvaltarregistrerade aktier krävs rösträttsregistrering senast den 7 november 2025. Aktieägare som representeras av ombud måste utfärda en skriftlig fullmakt. En dagordning för stämman inkluderar bland annat val av ordförande och beslut om bemyndigande för styrelsen att genomföra emissioner. Styrelsen föreslår att de får rätt att emittera aktier eller teckningsoptioner upp till 1 243 067 stycken, vilket motsvarar en maximal utspädning om cirka 12 procent. Förslaget kräver två tredjedelars majoritet för att godkännas. Aktieägare har rätt att ställa frågor under stämman. Fullständiga förslag och handlingar kommer att finnas tillgängliga två veckor före stämman. Det finns 9 115 826 utestående aktier och röster i bolaget, med ytterligare 493 615 aktier under registrering. Personuppgifter hanteras enligt Euroclears integritetspolicy. För mer information kan CEO Anders Dahlgren kontaktas.

Valega collaborates with financial institutions, advisory firms, and law enforcement across Europe, North America, and Asia, working with entities like Softronic, Europol, and North American government agencies. It has developed a comprehensive crypto intelligence database over six years, offering a competitive advantage. Valega's compliance architecture integrates transaction monitoring, risk intelligence, forensics, auditability, and reporting, aiming to replace fragmented systems and become a strategic partner in finance. Digital assets are increasingly entering the regulated financial system. Tobias Mathiasen from Katalysen notes that financial institutions seek partners with technical and regulatory expertise. Valega is well-positioned to meet these needs as tokenized assets are projected to grow significantly. Valega has been involved in major investigations and regulatory framework contributions, gaining recognition from international bodies. Valega is expanding commercially in the UK, Germany, and North America, with revenues doubling annually. Its goal is to lead in digital asset governance, risk, and compliance within two years. Peter Almberg of Katalysen highlights Valega's strong data foundation and trusted partnerships, which attract institutions entering the digital asset space. Valega is a core investment for Katalysen, comprising over 70% of its portfolio value, with Katalysen owning more than 20% of Valega. Katalysen supports its investments with capital, expertise, and strategic guidance for long-term value creation.

Katalysen's board of directors has decided to conduct a directed share issue, deviating from shareholders' preferential rights, by issuing 493,615 new shares to eight Swedish and international partners. The subscription price is set at SEK 6, which is approximately a 10.04% discount compared to the volume-weighted average price from mid-September to late October. The board believes this price reflects current market conditions and demand. Due to market volatility, the costs associated with a rights issue would likely surpass the discount value of this directed issue. Payment is due by October 28, 2025, with the board retaining the option to extend the deadline. The board chose a directed issue over a rights issue, as recent rights issues have struggled due to market conditions, and subscription levels have been low. The board believes this approach is more time- and cost-effective for the company's development. As a result, the total number of shares will increase from 9,115,826 to 9,609,441, and share capital will rise from SEK 1,185,057.38 to SEK 1,249,227.33, causing a dilution of approximately 5% for existing shareholders.

S4DX is a medtech company focused on improving the pre-analytical phase of blood sample diagnostics, providing a hybrid software and hardware solution that ensures full traceability and integrity of samples from collection to laboratory analysis. Recently, S4DX began operations in the UK by shipping 180 SmartTubes to a new partner, marking the start of its UK expansion. This move aligns with the UK's shift towards stricter quality standards, such as ISO 15189:2022, which demands comprehensive traceability in the pre-analytical phase. S4DX's technology records various parameters of blood samples during transport, offering real-time data integrated into laboratory systems. The company's solution is already deployed in twelve countries and is supported by partnerships with major players like Beckman Coulter, Roche, and Siemens Healthineers. S4DX is positioned for growth, having reached product-market fit and experiencing increasing demand from both customers and strategic partners. It is part of Katalysen's core investment portfolio, which emphasizes strong technology foundations and scaling potential. S4DX aims to enhance patient safety, reduce costs, and provide reliable diagnostics through its innovative platform.

Stockholmsbaserade QuTEM har nått ett viktigt steg i sitt uppdrag att förbättra kvaliteten och säkerheten hos nästa generations läkemedel. En ny studie i Molecular Therapy: Methods & Clinical Development visar att QuTEM:s innovativa elektronmikroskopiteknologi och bildanalys är en tillförlitlig och precis standard för att analysera byggstenarna i genterapi. I samarbete med Viralgen SL, en ledare inom tillverkning av genterapivektorer, har QuTEM:s metod visat sig vara mer tillförlitlig än flera etablerade tekniker, vilket pekar på dess potential som en ny standard för kvalitetskontroll inom genterapi. Josefina Nilsson, VD för QuTEM, noterar att erkännandet bekräftar QuTEM:s roll som en potentiell guldstandard för kvalitetskontroll inom genterapi, och att stora läkemedelsföretag har börjat outsourca en viktig del av sin kvalitetskontroll till QuTEM. Detta framhäver företagets växande relevans på en snabbt växande global marknad för genterapi, där efterfrågan på tillförlitliga kvalitetskontrollverktyg förväntas öka kraftigt. QuTEM:s metod erbjuder ett mer exakt sätt att skilja mellan fulla, delvis fyllda och tomma AAV-partiklar, och har utvecklats enligt internationella kvalitetsriktlinjer och opererar under ett GMP-certifikat från den svenska Läkemedelsverket. Deras metod är redan integrerad som en viktig kvalitetskontrollmätning och frigivningstest för genterapiprodukter, vilket stöder både bioteknikinnovatörer och stora läkemedelsföretag.

Sweden has over 400,000 unlisted and private companies, crucial for entrepreneurship, job creation, and innovation. However, these companies often face challenges due to outdated infrastructure, with ownership tracked in spreadsheets and inefficient fundraising processes. Alternativa, through its service eAktiebok, supports over 1,000 clients and aims to modernize this sector by scaling effective solutions, introducing new digital tools, and enhancing transparency and efficiency in the Swedish private company market. Led by CEO Martin N. Larsson, who has extensive experience in trading and finance, Alternativa is well-positioned to improve Sweden's private company infrastructure. With partners Katalysen and Apollonian, the company is working to create a modern ecosystem that facilitates efficient capital raising and clear governance for private companies. While currently focused on Sweden, Alternativa aims to expand internationally, addressing the global need for improved private company infrastructure. Tobias Mathiasen from Katalysen highlights three trends: increasing capital in unlisted companies, potential regulatory changes, and evolving fundraising infrastructure. These trends present opportunities for platforms like Alternativa to help unlisted companies adapt. Katalysen views Alternativa as a key investment, reflecting confidence in its potential to transform this sector. For more details on Katalysen Ventures, contact CEO Anders Dahlgren.

Under perioden 2024-06-05 till 2025-08-31 utnyttjades totalt 614'436 teckningsoptioner för att teckna 614'436 nya aktier i företaget, vilket motsvarar en teckningsgrad på 51,2 % av alla utfärdade optioner. Det finns för närvarande inga utestående optioner på Katalysens aktier, och alla nya aktier som utfärdats genom utnyttjande av optioner har registrerats hos Bolagsverket. Det totala antalet aktier i företaget är oförändrat sedan senast kommunicerat (9'115'826). För mer information om Katalysen Ventures, kontakta VD Anders Dahlgren via e-post: ad@katalysen.com eller besök www.katalysen.com.

Katalysen Ventures AB reported significant progress in the last quarter, highlighted by new Venture Targeter agreements and increased involvement with VALEGA Chain Analytics, resulting in doubled revenues for VALEGA in the first half of 2025 compared to 2024. The company added two new ventures, Syncro Group and Alternativa, to its portfolio, which will enhance value in the next quarter. Financially, Katalysen saw a 51% increase in revenue to SEK 0.8 million and a 45% reduction in operating losses compared to the previous year. Despite reducing valuations in four portfolio companies, the overall portfolio value rose from SEK 131 million to SEK 135 million. The company conducted a rights issue, raising approximately SEK 4.9 million to support operational initiatives. Katalysen remains focused on six key portfolio companies with strong potential and is preparing for potential asset sales and exits to strengthen liquidity and portfolio value. The company held its AGM, re-elected its auditor, and transitioned Peter Almberg to Executive Chairman, with Anders Dahlgren taking over as CEO. Important transactions and rights issues were completed, contributing to the overall strategic goals.

Between 24 June and 8 July 2025, Katalysen conducted a rights issue of shares, raising approximately SEK 5.5 million before costs. The issue has been registered, with the last trading day for BTA on 23 July 2025, and shares expected to be delivered around 29 July 2025. Katalysen engaged Sedermera Corporate Finance AB, Foyen Advokatfirma, and Nordic Issuing AB as advisors. The press release includes legal disclaimers about distribution restrictions and clarifies that it is not a prospectus. It also contains forward-looking statements, noting they are based on assumptions and subject to risks and uncertainties.